Two directors resign from Alignment Healthcare board; Margolis enters consulting role
Alignment Healthcare, Inc.
Jeffrey Margolis and Thomas Carella resigned from board effective Aug 13-14, 2024; board reduced from 11 to 9 directors.
Margolis entered consulting agreement with subsidiary for advisory services on IT and AI; monthly retainer ranges from $9,167 to $21,667 through June 2026.
Board reclassified Margaret McCarthy from Class I to Class III and restructured committee assignments to comply with Nasdaq listing standards.
On August 13, 2024 and August 14, 2024, respectively, Jeffrey Margolis and Thomas Carella each notified the Board of Directors (the "Board") of Alignment Healthcare, Inc. (the "Company") of their decision to resign as a member of the Board, effective immediately.
On August 13, 2024 and August 14, 2024, respectively, Jeffrey Margolis and Thomas Carella each notified the Board of Directors (the "Board") of Alignment Healthcare, Inc. (the "Company") of their decision to resign as a member of the Board, effective immediately.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Jeffrey Margolis resigned as Director at Alignment Healthcare, Inc..
Action
resigned
Role
Director
Exact text from the filing
On August 13, 2024 and August 14, 2024, respectively, Jeffrey Margolis and Thomas Carella each notified the Board of Directors (the "Board") of Alignment Healthcare, Inc. (the "Company") of their decision to resign as a member of the Board, effective immediately.
Thomas Carella resigned as Director at Alignment Healthcare, Inc..
Action
resigned
Role
Director
Exact text from the filing
On August 13, 2024 and August 14, 2024, respectively, Jeffrey Margolis and Thomas Carella each notified the Board of Directors (the "Board") of Alignment Healthcare, Inc. (the "Company") of their decision to resign as a member of the Board, effective immediately.
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.